| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8771774 | The Journal of Urology | 2018 | 33 Pages |
Abstract
Based on the available data, there appears to be no role for traditional immunotherapy as adjuvant treatment in patients with high risk localized kidney cancer following surgical resection. S-TRAC provides evidence that 1 year of adjuvant sunitinib in patients with higher risk locoregional disease increases the median time to recurrence. However, the data on overall survival are immature and adverse effects are common. Results from trials investigating immune checkpoint inhibitors are highly anticipated.
Keywords
national clinical trialAssureRFSDFSECoGIL-2NCTCAIXAdjuvantsImmunologicinterferonIFNInterleukin-2disease-free survivalRecurrence-free survivaloverall survivalHigh doseRenal celleastern cooperative oncology groupVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Kidney neoplasmsCarcinomaCarbonic anhydrase IX
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Andrew T. Lenis, Nicholas M. Donin, David C. Johnson, Izak Faiena, Amirali Salmasi, Alexandra Drakaki, Arie Belldegrun, Allan Pantuck, Karim Chamie,